Sector: Healthcare | Industry: Biotechnology & Medical Research |
Company Contact | |
Address: | 201-2067 Cadboro Bay Rd. VICTORIA BC V8R 5G4 |
Tel: | 1-416-4271235 |
Website: | https://eupraxiapharma.com/home/default.aspx |
IR: | See website |
Key People | ||
Simon Pimstone Non-Executive Independent Chairman of the Board | Bruce G. Cousins President, Chief Financial Officer | James A. Helliwell Chief Executive Officer, Director |
Amanda Malone Chief Scientific Officer | Paul A. Brennan Chief Business Officer |
Business Overview |
Eupraxia Pharmaceuticals Inc. is a Canada-based clinical-stage biotechnology company. The Company is focused on the development of locally delivered, extended-release alternatives to approved drugs. The Company's principal business is the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product candidate, EP-104IAR, is designed to meet the unmet medical need and market demand for long-lasting pain relief for knee osteoarthritis (OA). The primary active ingredient of the EP-104 products consists of a solid core of fluticasone propionate (FP) coated with an outer layer of polyvinyl alcohol (PVA). Its lead product candidate is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms and is used corticosteroid with systemic safety record. EP-104 is in Phase Ib/IIa clinical development. |
Financial Overview |
For the fiscal year ended 31 December 2023, Eupraxia Pharmaceuticals Inc revenues was not reported. Net loss increased 53% to $28.2M. Higher net loss reflects Research and development - Balan increase of 52% to $20.5M (expense), Professional fees increase from $269K to $2.8M (expense), Salaries and benefits (net) increase of 37% to $2.2M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.96 to -$1.17. |
Employees: | 29 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $119.16M as of Dec 31, 2023 |
Annual revenue (TTM): | $0.00M as of Dec 31, 2023 |
EBITDA (TTM): | -$37.54M as of Dec 31, 2023 |
Net annual income (TTM): | -$38.85M as of Dec 31, 2023 |
Free cash flow (TTM): | -$28.57M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 35,622,553 as of Mar 27, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |